Wang Zhenyi, male, born in Xinghua, Jiangsu, is currently tenured professor at Medical School of Shanghai Jiao Tong University, Doctoral Supervisor, haematologist, the first expert in thrombus and haemostasis in China. Now, he serves as honorary director of Shanghai Haematology Research Center, honorary editor-in-chief on The Chinese Journal of Hematology , vice editor-in-chief on Foreign Medical Sciences Blood Transfusion and Hematology (fascicule), council member of International Society for Heart Research and International Society on Thrombosis and Haemostasis (ISTH), and academician of The French Academy of Science. He got his Medical Doctorate from Medical School, Aurora University in 1948. He acted successively as director of Research Center of Medicine and Pathophysiology at Shanghai Second Medical University, dean of Basic Medicine Department, president of Shanghai Second Medical University, and director of Shanghai Haematology Research Center. He also used to be council member of Shanghai Physiology Association, vice team-leader of Shanghai Haematology Department, Chinese Medical Association, and chief editor on Chinese Haematological Journal. He has published, as editor-in-chief, 3 books, such as Primary Theory and Clinic of Thrombosis and Haemostasia, and, as editor and translator, Hemorrhage Diseases, as well as other 14 monographs. He is the author of more than 200 scientific papers, including “Clinical Application of Anti-VIIIR Ag Antiserum” and “Variability of Pseudo Von Willebrand Disease (vWD)”. He was elected academician of the Chinese Academy of Engineering in December, 1994. Title: Academician of the Chinese Academy of Engineering.
Professor Wang Zhenyi has been engaged in the teaching and research work of internal medicine and haematology surgery for 45 years. He has been successively engaged in teaching at Foundation of Internal Medicine, General Internal Medicine, Haematology, Pathophysiology etc., and has supervised 11 Ph D candidates and 43 M.A. candidates. He began his research on hemorrhage diseases in 1954, and reported for the first time in China the methods of dealing with haemophilia. He was the first to find in the 1950s the effect that the front part of fresh Cattail Pollen (Pu Huang), a Chinese traditional medical term, had on the formation of atherosclerotic plaque of artery in experimental rabbits. The research was intermitted for some reason till mid-1980s, and then in cooperation with Graduate School of the Chinese Academy of Sciences , he, together with his team, separated four useful compositions from cattail pollen, ascertained their chemical results, and elucidated their effects on preventing the formation of atherosclerotic plaque of artery, which brought him the honor of the second prize of the Scientific Development Award by the State Educational Committee. Under his leadership, the research group, for the first time in China, purified the vWF in mid-1980s, established methods of detecting the antigen and function of vWF, and ways of checking Haemophilia-A carriers, thus was awarded for two times the second prize of scientific research by Health Ministry. Also for the first time in China, the research group purified and tested Protein-C and Protein-S, β- thromboglobulin and platelet factor 4, and discovered and reported Protein-S deficiency disease. The research on separating, purifying, and preparing antiserum of platelet protein, and on immunoradiometric assay earned for him and his team Technological Achievement Award from Shanghai Second Medical University in 1985. The study of inducing differentiation therapy with All Trans Retinoic Acid (ATRA) in Acute Promyelocytic Leukemia (APL) won the third prize of the Scientific Development Award from Health Ministry in 1989 and the Excellence Prize at the First Shanghai Exposition of Science and Technology in 1991. The project gained the third prize of the Sixth National Award for Natural Sciences and the second prize of Scientific Development Award from the State Educational Committee in 1993. The project of Molecular study on human leukemias and their clinical application won the second prize of the National Scientific Development Award in 1995 and the second prize of Scientific Development Award from the State Educational Committee in 1995. His study of PHI Chromosome related Leukemias Cells and Molecular Biology won the first prize of Shanghai Scientific Development Award in 1994 and the first prize of Scientific Development Award from the State Educational Committee in 1995.
In the late 1970s, Professor Wang saw many patients of acute haemophilia, especially of acute promyelocytic leukemia, who died without effective treatments, or died because of the adverse reactions of chemotherapy. Motivated by his vocational moral, Professor Wang decided to start his study on haemophilia. Influenced by the Confucian idea of “Give up evil and return to good”, as well as the overseas research in which tumor cells, after extracorporeal inducing differentiation, could be changed into comparatively mature normal cells, he engaged himself in the study of inducing differentiation therapy for tumor. Some research of making differentiation inducers failed from the year 1979 to 1986. In 1986, based on the successful extracorporal experience, he treated acute promyelocytic leukemia with homemade all trans retinoic acid (ATRA), which was the first attempt in the world, and achieved satisfactory results. Some dying patients were saved. In the following 2 years, experts in France, Japan, and US acknowledged this result. Up to now, about 85-90% of acute promyelocytic leukemia patients have been treated with ATRA therapy, which generates less adverse reactions, does not restrain hematopoiesis or cause haemorrhage, and is easy to perform and cheap. It provides not only a new therapy for treating acute leukemia, which was once thought of being difficult to deal with and of high death rate, but also the theory and way of treating tumor with inducing differentiation therapy, and also an example recognized by both domestic and international experts. In 1994, judges of Cancer Research Fund of General Motors Corp. considered it as an important research achievement, which made great contribution to tumor treatment research, and awarded it Kettering Cancer Research Prize. According to statistics, his "Study of Inducing Differentiation Therapy with All Trans Retinoic Acid (ATRA) in Acute Promyelocytic Leukemia (APL)", published in 1988 by the international journal Blood, had been cited for more than 370 times till the year 1992, which was among the most-frequently-cited papers in China, and started a research upsurge in this field. Professor Wang was also awarded Qiu-Shi Outstanding Scientist Prize in 1996 in China and Brutpbacher Prize of Cancer Research in Switzerland in March 1993.